drugset / Trial / NCT06302582

Platelet Rich Plasma Combined With Human Umbilical Cord Mesenchymal Stem Cells for Stage 3 and 4 Stress Injury

NCT06302582

Phase 1/2 Unknown 40 enrolled Liaocheng People's Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is an open-label, single-center trial which aim to evaluate of efficacy and safety of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) combined with platelet-rich plasma (PRP) in stage 3 and 4 stress injury.

Timeline

Start
2024-02-29
Primary completion
2024-11-25
Completion
2024-11-25

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Platelet Rich Plasma Other / unclassified 2 ml Other
Subject Platelet Rich Plasma Other / unclassified 3 ml Other
Subject human umbilical cord mesenchymal stem cells Cell therapy 5e+06 cells Other
Background thrombin Protein / enzyme biologic Other

Indications